Samuel Jack Vidal, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Capsid | 1 | 2021 | 435 | 0.640 |
Why?
|
| Capsid Proteins | 1 | 2021 | 468 | 0.610 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2021 | 545 | 0.570 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 1356 | 0.560 |
Why?
|
| Simian immunodeficiency virus | 1 | 2021 | 814 | 0.530 |
Why?
|
| GATA2 Transcription Factor | 1 | 2015 | 158 | 0.470 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 2009 | 0.420 |
Why?
|
| Cytological Techniques | 1 | 2014 | 218 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 1795 | 0.390 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3215 | 0.360 |
Why?
|
| Pandemics | 1 | 2021 | 8749 | 0.180 |
Why?
|
| Macaca mulatta | 3 | 2022 | 2365 | 0.180 |
Why?
|
| Cross Reactions | 1 | 2021 | 828 | 0.160 |
Why?
|
| Thrombosis | 2 | 2022 | 2956 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 11230 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2015 | 271 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2020 | 1163 | 0.100 |
Why?
|
| Receptor, Insulin | 1 | 2015 | 838 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13698 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 5342 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2014 | 1081 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 3621 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 668 | 0.080 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 1231 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 771 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 751 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 22389 | 0.060 |
Why?
|
| Animals | 6 | 2022 | 169335 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2015 | 4032 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2014 | 5906 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2020 | 131 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3952 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10486 | 0.040 |
Why?
|
| Complement Activation | 1 | 2020 | 447 | 0.040 |
Why?
|
| Cricetinae | 1 | 2022 | 2423 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2020 | 644 | 0.030 |
Why?
|
| Male | 5 | 2021 | 365203 | 0.030 |
Why?
|
| Humans | 8 | 2024 | 768970 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 23653 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2022 | 4148 | 0.030 |
Why?
|
| Vaccination | 1 | 2024 | 3438 | 0.020 |
Why?
|
| Inflammation | 2 | 2022 | 10868 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 82072 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3859 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 1839 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2631 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 223851 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 1408 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5801 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7453 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2460 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 10099 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 17629 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 9527 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 17173 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13674 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59739 | 0.010 |
Why?
|
| Female | 1 | 2020 | 397515 | 0.000 |
Why?
|